In order to evaluate the therapeutic effects of risperidone, a combined serotonin-S： and dopamine-D2 receptor antagonist 19 patients with chronic schizophrenia were studied for 16 weeks in a single-open study. After a wash-out period of 7 days, risperidone was administered and patients were evaluated by means of the Positive and Negative Syndrome Scale (PANSS) 8 times. The results were as follows 1) On the PANSS positive subscale, there was significant improvement of positive symptoms after 2 weeks(p<.05) and 8 weeks(P〈.0001) administration. 2) On the PANSS negative subscale, there was significant improvement of negative symptoms after 2 weeks(P<C.05) and 6 weeks(P< .0 0 1) administration, and negative subtype group has more significantCP<.05) improvement of negative symptoms than positive subtype group. 3) On the PA NSS general psychopathology subscale, there was significant improvement of general psychopathologic symptoms after 4 weeks (P < .0 l) and 8 weeks(P〈.0001) administration. 4) At the end of the study, mean daily dosage were risperidone, 11.18± 4.59mg, and the range was 2.5 〜 20mg. The above results suggest that risperidone has therapeutic effects in all PANSS subscales, and has significant results in improvement of negative symptoms, especially.
서 론
연구대상 및 방법
연구결과
고 찰
결 론
References